58 related articles for article (PubMed ID: 4274502)
21. [Vaccination therapy of melanoma].
Schuler-Thurner B; Schuler G
J Dtsch Dermatol Ges; 2005 Aug; 3(8):630-45. PubMed ID: 16033483
[No Abstract] [Full Text] [Related]
22. Current concepts of the biology of human cutaneous malignant melanoma.
Clark WH; Mastrangelo MJ; Ainsworth AM; Berd D; Bellet RE; Bernardino EA
Adv Cancer Res; 1977; 24():267-338. PubMed ID: 322460
[No Abstract] [Full Text] [Related]
23. Malignant melanoma and its therapy: a review.
Chanda JJ; Callen JP; Stawiski MA
Cutis; 1979 Jun; 23(6):759-83. PubMed ID: 380931
[TBL] [Abstract][Full Text] [Related]
24. [Future of malignant stage I melanoma. Immunology and immunotherapy].
Nicolas JF; Berthier O; Trillet-Lenoir V; Claudy A; Revillard JP
Ann Dermatol Venereol; 1995; 122(5):324-35. PubMed ID: 8572476
[No Abstract] [Full Text] [Related]
25. [To outwit melanoma with its own tricks].
Bischoff A
MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
[No Abstract] [Full Text] [Related]
26. Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms.
Nathanson
Natl Cancer Inst Monogr; 1976 Nov; 44():67-76. PubMed ID: 799762
[TBL] [Abstract][Full Text] [Related]
27. Melanoma as a model tumour for immuno-oncology.
Maio M
Ann Oncol; 2012 Sep; 23 Suppl 8():viii10-4. PubMed ID: 22918922
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy for the management of advanced melanoma: the next steps.
Zikich D; Schachter J; Besser MJ
Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
[TBL] [Abstract][Full Text] [Related]
29. Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate.
Scoggin SD; Sivanandham M; Sperry RG; Wallack MK
Ann Plast Surg; 1992 Jan; 28(1):108-9. PubMed ID: 1642396
[TBL] [Abstract][Full Text] [Related]
30. Spontaneous regression of metastases from melanoma: review of the literature.
Kalialis LV; Drzewiecki KT; Klyver H
Melanoma Res; 2009 Oct; 19(5):275-82. PubMed ID: 19633580
[TBL] [Abstract][Full Text] [Related]
31. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.
Damian DL; Saw RP; Thompson JF
J Surg Oncol; 2014 Mar; 109(4):308-13. PubMed ID: 24522938
[TBL] [Abstract][Full Text] [Related]
32. Tumor-directed immune reactivity and immunotherapy in malignant melanoma. Current status.
Mavligit G; Gutterman JU; McBride C; Hersh EM
Prog Exp Tumor Res; 1974; 19():222-52. PubMed ID: 4612607
[No Abstract] [Full Text] [Related]
33. Immunologic factors in melanoma.
Donawho CK; Kripke ML
Clin Dermatol; 1992; 10(1):69-74. PubMed ID: 1504930
[No Abstract] [Full Text] [Related]
34. Current management of melanoma.
Seigler HF; Fetter BF
Ann Surg; 1977 Jul; 186(1):1-12. PubMed ID: 327949
[No Abstract] [Full Text] [Related]
35. [New aspects of immunotherapy of malignant melanoma].
Enk A
Praxis (Bern 1994); 2001 Mar; 90(10):403-6. PubMed ID: 11305186
[TBL] [Abstract][Full Text] [Related]
36. [Active specific immunotherapy of malignant melanoma].
Lotem M; Shiloni E; Ingber A; Peretz T
Harefuah; 1997 Aug; 133(3-4):122-6. PubMed ID: 9332080
[No Abstract] [Full Text] [Related]
37. [Role of MHC class I molecules in anti-tumoral mechanisms in human malignant melanoma].
Dissemond J; Grabbe S
Hautarzt; 2006 Aug; 57(8):690-6. PubMed ID: 16163561
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of melanoma.
Chapman PB
Cancer Chemother Biol Response Modif; 2002; 20():371-83. PubMed ID: 12703215
[No Abstract] [Full Text] [Related]
39. The Immunology of Melanoma.
Ko JS
Clin Lab Med; 2017 Sep; 37(3):449-471. PubMed ID: 28802495
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of immunotherapy for metastatic mucosal melanoma.
Shreders A; Joseph RW
Immunotherapy; 2016 Jul; 8(8):843-5. PubMed ID: 27381682
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
